ESR1 and breast carcinoma: CDK4/6 inhibitors (palbociclib, ribociclib and abemaciclib) in combination with hormone therapies are currently approved by the FDA to treat patients with estrogen receptor positive (ER+) and HER 2 negative breast cancers.